Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Tyring

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
The Journal of Dermatological Treatment|November 12, 2016
Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasisNeil J Korman, Howard Sofen, Scott Fretzin, et al.
Journal of Drugs in Dermatology : JDD|July 10, 2014
Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trialThomas Bieber, Olivier Chosidow, Neil Bodsworth, et al.
Journal of Drugs in Dermatology : JDD|October 11, 2022
Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe AcneJames Del Rosso, Linda Stein Gold, Stephen Tyring, et al.
The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trialChristopher M Hull, Johan Harmenberg, Eva Arlander, et al.
Journal of the American Academy of Dermatology|November 2, 2007
Epidermodysplasia verruciformis in the setting of graft-versus-host diseaseJoy H Kunishige, Sharon R Hymes, Vandana Madkan, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
Dermatopathology (Basel, Switzerland)|April 6, 2016
Adolescent Onset of Localized Papillomatosis, Lymphedema, and Multiple Beta-Papillomavirus Infection: Epidermal Nevus, Segmental Lymphedema Praecox, or Verrucosis? A Case Report and Case Series of Epidermal NeviPooja Kadam, Janne Rand, Peter Rady, et al.
Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
The Journal of Dermatological Treatment|November 12, 2016
Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasisNeil J Korman, Howard Sofen, Scott Fretzin, et al.
Journal of Drugs in Dermatology : JDD|July 10, 2014
Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trialThomas Bieber, Olivier Chosidow, Neil Bodsworth, et al.
Journal of Drugs in Dermatology : JDD|October 11, 2022
Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe AcneJames Del Rosso, Linda Stein Gold, Stephen Tyring, et al.
The Journal of Dermatological Treatment|July 4, 2019
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasisBoni Elewski, Alan Menter, Jeffrey Crowley, et al.
Journal of the American Academy of Dermatology|September 21, 2010
Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trialChristopher M Hull, Johan Harmenberg, Eva Arlander, et al.
Journal of the American Academy of Dermatology|November 2, 2007
Epidermodysplasia verruciformis in the setting of graft-versus-host diseaseJoy H Kunishige, Sharon R Hymes, Vandana Madkan, et al.
Lancet (London, England)|January 10, 2006
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialStephen Tyring, Alice Gottlieb, Kim Papp, et al.
Dermatopathology (Basel, Switzerland)|April 6, 2016
Adolescent Onset of Localized Papillomatosis, Lymphedema, and Multiple Beta-Papillomavirus Infection: Epidermal Nevus, Segmental Lymphedema Praecox, or Verrucosis? A Case Report and Case Series of Epidermal NeviPooja Kadam, Janne Rand, Peter Rady, et al.
Journal of the American Academy of Dermatology|February 8, 2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind studyAbby S Van Voorhees, Linda Stein Gold, Mark Lebwohl, et al.
Pageof 13